Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice

References

• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719–2747.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Calderón A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. Rev Esp Cardiol. 2014;67:150–151.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kevin F, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk insights from the NCDR PINNACLE registry. JAMA Cardiol. 2016;1:55–62.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al.; GARFIELD Registry Investigators. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One. 2013;8:e63479.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Kim S, Thomas L, et al.; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014;129:2005–2012.
   PubMed Web of Science ®Google Scholar
• Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. BMC Neurol. 2015;15:129.
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderon A, Escobar C, et al. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol. 2012;65:47–53.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887–1892.
   PubMed Web of Science ®Google Scholar
• Tanislav C, Milde S, Schwartzkopff S, et al. Baseline characteristics in stroke patients with atrial fibrillation: clinical trials versus clinical practice. BMC Res Notes. 2015;8:262.
   PubMedGoogle Scholar
• Barón-Esquivias G, Fernández-Avilés F, Atienza F, et al. Efficacy and safety of rivaroxaban in real-life patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2015;13:341–353.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation. Semergen. 2016 Mar 4. [Epub ahead of print].
   Google Scholar
• European Medicines Agency (EMA). Xarelto®, “summary of product characteristics”. [updated 2016 Jun 10]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther. 2013;11:129–141.
   PubMedGoogle Scholar
• Barrios V, Górriz JL. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. J Comp Eff Res. 2015;4:651–664.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549–558.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Perzborn E, Berkowitz SD. The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol. 2013;4:145.
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, et al. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. J Clin Pharmacol. 2013;53:249–255.
   PubMed Web of Science ®Google Scholar
• Girgis IG, Patel MR, Peters GR, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF. J Clin Pharmacol. 2014;54:917–927.
   PubMed Web of Science ®Google Scholar
• Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost. 2016;14:1308–1313.
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J. 2012;76:2104–2111.
   PubMed Web of Science ®Google Scholar
• Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888–2899.
   PubMed Web of Science ®Google Scholar
• Dias C, Moore KT, Murphy J, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43:229–236.
   PubMed Web of Science ®Google Scholar
• Escobar C, Arceluz M, Montes de Oca R, et al. Concomitant administration of rivaroxaban and dronedarone in patients with nonvalvular atrial fibrillation. Rev Esp Cardiol. 2017; 70(2):121–122.
   Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Hecker J, Marten S, Keller L, et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry. Thromb Haemost. 2016;115:939–949.
   PubMed Web of Science ®Google Scholar
• Tamayo S, Patel M, Yuan Z, et al. Post-marketing pharmacovigilance study for the active detection and evaluation of major bleeding in rivaroxaban users with non-valvular atrial fibrillation. J Am Coll Cardiol. 2015;65:A281.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–1153.
   PubMed Web of Science ®Google Scholar
• Engelberger RP, Noll G, Schmidt D, et al. Initiation of rivaroxaban in patients with nonvalvular atrial fibrillation at the primary care level: the Swiss Therapy in Atrial fibrillation for the Regulation of coagulation *(STAR) study. Eur J Intern Med. 2015;26:508–514.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M, Ehlken B, et al. REal-LIfe Evidence of stroke prevention in patients with atrial Fibrillation – the RELIEF study. Int J Cardiol. 2016;203:882–884.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315–322.
   PubMed Web of Science ®Google Scholar
• Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;130:138–146.
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF trial). Am Heart J. 2015;170(675–82.e8.
   PubMed Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387–2394.
   PubMed Web of Science ®Google Scholar
• Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF. Circulation. 2016;134:37–47.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014;35:233–241.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5:e002197.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375(25):2423–2434.
   Web of Science ®Google Scholar
• van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail. 2013;6:740–747.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hellkamp AS, Lokhnygina Y, et al. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc. 2014;3:e000521.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133:352–360.
   PubMed Web of Science ®Google Scholar
• Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. Heart Rhythm. 2014;11:925–932.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61:1998–2006.
   PubMed Web of Science ®Google Scholar
• Cappato R, Ezekowitz MD, Klein AL, et al.; on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35:3346–3355.
   PubMed Web of Science ®Google Scholar
• Patel MR, Hellkamp AS, Fox KA; ROCKET AF Executive Committee and Investigators. Point-of-care warfarin monitoring in the ROCKET AF trial. N Engl J Med. 2016;374:785–788.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124:955–962.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Gelbricht V, Forster K, et al. Safety of switching from vitamin-K antagonists to dabigatran or rivaroxaban in daily care – results from the Dresden NOAC registry. Br J Clin Pharmacol. 2014;78:908–917.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Gelbricht V, Forster K, et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35:1888–1896.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Förster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015;17:530–538.
   PubMed Web of Science ®Google Scholar
• Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol. 2015;38:63–68.
   PubMed Web of Science ®Google Scholar
• Peacock F, Patel M, Tamayo S, et al. Major bleeding in a post-marketing assessment of 39,052 non-valvular atrial fibrillation patients on rivaroxaban. ESC. 2015. 29 Aug–2 Sep. Abstract P4066.
   Google Scholar
• Tamayo S, Patel M, Yuan Z, et al. Incidence and characteristics of major bleeding among rivaroxaban users with renal disease and non-valvular atrial fibrillation. Circulation. 2015;132(Suppl. 3):A15905.
   Google Scholar
• Coleman CI, Haas S, Turpie AG, et al. Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol. 2016;39:565–569.
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Fernández-Díaz E, García-García J, et al. Efficacy, safety and tolerability of rivaroxaban for the secondary prevention of stroke in patients with atrial fibrillation in clinical practice. Future Neurology. 2015;10:529–536.
   Web of Science ®Google Scholar
• Coleman CI, Antz M, Simard E, et al. Real-world evidence of stroke prevention in patients with non-valvular atrial fibrillation in the United States: the REVISIT-US study. Presented at 2016 European Society of Cardiology Congress; Aug 27–31; Rome, Italy. Abstract 2576.
   Google Scholar
• Nelson WW, Song X, Coleman CI, et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin. 2014;30:2461–2469.
   PubMed Web of Science ®Google Scholar
• Monaco L, Biagi C, Conti V, et al. Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol. 2017.Jan.10. [Epub ahead of print].
   PubMedGoogle Scholar
• Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2016 Dec 30. [Epub ahead of print].
   Web of Science ®Google Scholar
• Sherid M, Sulaiman S, Samo S, et al. Risk of gastrointestinal bleeding with rivaroxaban: a comparative study with warfarin. Gastroenterol Res Pract. 2016;2016:9589036.
   PubMed Web of Science ®Google Scholar
• Sherwood MW, Nessel CC, Hellkamp AS, et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial. J Am Coll Cardiol. 2015;66:2271–2281.
   PubMed Web of Science ®Google Scholar
• Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873–1880.
   PubMed Web of Science ®Google Scholar
• Mar F, Crowther M, Gold A, et al. Andexanet alfa: an investigational universal antidote for reversal of anticoagulation of factor Xa inhibitors in healthy human volunteers. Neurosurgery. 2016;63(Suppl 1):170.
   PubMedGoogle Scholar
• Hussain SS, Tyroch AH, Mukherjee D. Reversal of newer direct oral anticoagulant drugs (DOACs). Cardiovasc Hematol Agents Med Chem. 2016 May 24. [Epub ahead of print].
   PubMedGoogle Scholar
• Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29:675–690.
   PubMed Web of Science ®Google Scholar
• Mensch A, Stock S, Stollenwerk B, et al. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation. Pharmacoeconomics. 2015;33:271–283.
   PubMed Web of Science ®Google Scholar
• Morais J, Aguiar C, McLeod E, et al. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Rev Port Cardiol. 2014;33:535–544.
   PubMedGoogle Scholar
• Kourlaba G, Maniadakis N, Andrikopoulos G, et al. Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece. Cost Eff Resour Alloc. 2014;12:5.
   PubMed Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics. 2013;31:909–918.
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012;110:845–851.
   PubMed Web of Science ®Google Scholar